The clinical utility of tau PET has recently been demonstrated in a multi-centre study highlighting the ability of [18F]flortaucipir to discriminate between AD dementia and non-AD neurodegenerative diseases, with highest sensitivity (96.8%) and specificity (87.9%) using several thresholds applied to temporal and temporoparietal regions [75]. The gene discussed is MAPT; the disease is Alzheimer disease.